Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes.

Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J, Strobel S, Wang Y, Burns C, Lush C, Weyer C, Horowitz M

Diabetologia21 Apr 2005Cited by 136 (Europe PMC)

PMID15843914DOI10.1007/s00125-005-1732-4PepBankPUB-15843914

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with type 2 diabetes or obesity, pramlintide did not affect meal duration compared with placebo.
In plain wordsIn men with diabetes or obesity, pramlintide did not change meal duration compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeMeal duration
Study
n = 26
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
120 microg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
Compared with placebo, pramlintide reduced energy intake in both the type 2 diabetes (Delta-202+/-64 kcal, -23+/-8%, p<0.01) and obese (Delta-170+/-68 kcal, -16+/-6%, p<0.02) groups, without affecting meal duration.
3 context sentences(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, placebo-controlled crossover study, 11 insulin-treated men with type 2 diabetes (age 60+/-9 years, BMI 28.9+/-4.8 kg/m(2)) and 15 non-diabetic obese men (age 41+/-21 years, BMI 34.4+/-4.5 kg/m(2)) underwent two standardised meal tests.
Summary · context
After fasting overnight, subjects received single subcutaneous injections of either pramlintide (120 microg) or placebo, followed by a preload meal.
Summary · context
After 1 h, subjects ate an ad libitum buffet meal.
Report a problemFND-1584391403
02HumanRandomized controlled trialMechanism
In men with diabetes or obesity, profiles suggested pramlintide may increase satiety independently of other anorexigenic gut peptides.
In plain wordsIn men with diabetes or obesity, profiles suggested pramlintide may increase fullness independently of other appetite-reducing gut peptides, compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseSatiogenic effect
Study
n = 26
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
120 microg · subcutaneous · single doseAs given in this study (human).
Source sentences
Summary
Hunger and hormonal analyte profiles provided evidence that pramlintide may exert a primary satiogenic effect, independently of other anorexigenic gut peptides.
3 context sentences(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, placebo-controlled crossover study, 11 insulin-treated men with type 2 diabetes (age 60+/-9 years, BMI 28.9+/-4.8 kg/m(2)) and 15 non-diabetic obese men (age 41+/-21 years, BMI 34.4+/-4.5 kg/m(2)) underwent two standardised meal tests.
Summary · context
After fasting overnight, subjects received single subcutaneous injections of either pramlintide (120 microg) or placebo, followed by a preload meal.
Summary · context
After 1 h, subjects ate an ad libitum buffet meal.
Report a problemFND-1584391404
03HumanRandomized controlled trialEfficacy outcome
In non-diabetic obese men, pramlintide reduced energy intake compared with placebo.
In plain wordsIn obese men without diabetes, pramlintide reduced food energy intake compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseEnergy intake in obesity
Study
n = 15
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
120 microg · subcutaneous · single doseAs given in this study (human).
Measurements
Energy intake difference
−170 kcal
obese group
Energy intake difference
−16%
obese group
Source sentences
Summary
Compared with placebo, pramlintide reduced energy intake in both the type 2 diabetes (Delta-202+/-64 kcal, -23+/-8%, p<0.01) and obese (Delta-170+/-68 kcal, -16+/-6%, p<0.02) groups, without affecting meal duration.
3 context sentences(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, placebo-controlled crossover study, 11 insulin-treated men with type 2 diabetes (age 60+/-9 years, BMI 28.9+/-4.8 kg/m(2)) and 15 non-diabetic obese men (age 41+/-21 years, BMI 34.4+/-4.5 kg/m(2)) underwent two standardised meal tests.
Summary · context
After fasting overnight, subjects received single subcutaneous injections of either pramlintide (120 microg) or placebo, followed by a preload meal.
Summary · context
After 1 h, subjects ate an ad libitum buffet meal.
Report a problemFND-1584391402
04HumanRandomized controlled trialEfficacy outcome
In insulin-treated men with type 2 diabetes, pramlintide reduced energy intake compared with placebo.
In plain wordsIn men with type 2 diabetes, pramlintide reduced food energy intake compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseEnergy intake in type 2 diabetes
Study
n = 11
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
120 microg · subcutaneous · single doseAs given in this study (human).
Measurements
Energy intake difference
−202 kcal
type 2 diabetes
Energy intake difference
−23%
type 2 diabetes
Source sentences
Summary
Compared with placebo, pramlintide reduced energy intake in both the type 2 diabetes (Delta-202+/-64 kcal, -23+/-8%, p<0.01) and obese (Delta-170+/-68 kcal, -16+/-6%, p<0.02) groups, without affecting meal duration.
3 context sentences(design, population, supporting numbers)
Summary · context
In this randomised, double-blind, placebo-controlled crossover study, 11 insulin-treated men with type 2 diabetes (age 60+/-9 years, BMI 28.9+/-4.8 kg/m(2)) and 15 non-diabetic obese men (age 41+/-21 years, BMI 34.4+/-4.5 kg/m(2)) underwent two standardised meal tests.
Summary · context
After fasting overnight, subjects received single subcutaneous injections of either pramlintide (120 microg) or placebo, followed by a preload meal.
Summary · context
After 1 h, subjects ate an ad libitum buffet meal.
Report a problemFND-1584391401

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.